768370-80-5

Downstream Products

• 1123813-12-6 (R)-N₂-[4-(trifluoromethyl)benzyl]-N₁-(4-chlorophenyl)-N₂-methylpyrrolidine-1,2-dicarboxamide 
• 1123813-20-6 (R)-N₂-(4-chloro-2-methylbenzyl)-N₁-(4-chlorophenyl)-N₂-methylpyrrolidine-1,2-dicarboxamide 
• 1123813-07-9 (R)-N₂-(4-cyanobenzyl)-N₁-(4-chlorophenyl)-N₂-methylpyrrolidine-1,2-dicarboxamide 
• 1123813-17-1 (R)-N₂-(4-methylbenzyl)-N₁-(4-chlorophenyl)-N₂-methylpyrrolidine-1,2-dicarboxamide 
• 1123813-10-4 (R)-N₂-(4-methoxybenzyl)-N₁-(4-chlorophenyl)-N₂-methylpyrrolidine-1,2-dicarboxamide 
• 1123813-00-2 (R)-N₂-(2-chlorobenzyl)-N₁-(4-chlorophenyl)-N₂-(2-hydroxyethyl)pyrrolidine-1,2-dicarboxamide 
• 1123813-03-5 (R)-N₂-(3-chlorobenzyl)-N₁-(4-chlorophenyl)-N₂-(2-hydroxyethyl)pyrrolidine-1,2-dicarboxamide 
• 1123813-23-9 (R)-N₂-(4-chloro-3-methylbenzyl)-N₁-(4-chlorophenyl)-N₂-methylpyrrolidine-1,2-dicarboxamide 

Relevant academic research and scientific papers

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.